{"id":"placebo-dummy-inhaler","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2105275","moleculeType":"Small molecule","molecularWeight":"155.28"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo inhalers are inert devices used as control comparators in clinical trials to measure the true efficacy of active medications against baseline and psychological expectation effects. They allow researchers to isolate the pharmacological benefit of a drug by accounting for patient expectation, symptom improvement from natural disease course, and other non-specific factors. The dummy inhaler is identical in appearance and use to active formulations but contains no therapeutic agent.","oneSentence":"A placebo inhaler delivers no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:40.661Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clinical trial control comparator (not a therapeutic indication)"}]},"trialDetails":[{"nctId":"NCT01577082","phase":"PHASE3","title":"Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-04-20","conditions":"Asthma","enrollment":542},{"nctId":"NCT04912596","phase":"NA","title":"Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma","status":"RECRUITING","sponsor":"Intech Biopharm Ltd.","startDate":"2022-08-15","conditions":"Mild Asthma","enrollment":148},{"nctId":"NCT01396278","phase":"PHASE2","title":"Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-01","conditions":"Asthma","enrollment":9},{"nctId":"NCT05165485","phase":"PHASE4","title":"Phase 4 COPD and Suboptimal Inspiratory Flow Rate","status":"COMPLETED","sponsor":"Theravance Biopharma","startDate":"2022-01-07","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":404},{"nctId":"NCT06618105","phase":"PHASE3","title":"Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) of Macleods Pharmaceuticals Ltd","status":"NOT_YET_RECRUITING","sponsor":"Macleods Pharmaceuticals Ltd","startDate":"2024-10-15","conditions":"Mild Asthma","enrollment":144},{"nctId":"NCT00092092","phase":"PHASE4","title":"Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-10","conditions":"Asthma, Bronchial","enrollment":71},{"nctId":"NCT05499572","phase":"","title":"Usability of Levodopa Cyclops™ vs INBRIJA® in Parkinson's Patients","status":"COMPLETED","sponsor":"Martini Hospital Groningen","startDate":"2024-02-29","conditions":"Usability","enrollment":16},{"nctId":"NCT01397162","phase":"PHASE2","title":"Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-21","conditions":"Asthma","enrollment":29},{"nctId":"NCT01397201","phase":"PHASE2","title":"Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-01","conditions":"Asthma","enrollment":30},{"nctId":"NCT01103349","phase":"PHASE2","title":"BI 671800 in Asthmatic Patients on Inhaled Corticosteroids","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-04-20","conditions":"Asthma","enrollment":243},{"nctId":"NCT02245672","phase":"PHASE3","title":"MGR001 / Advair Diskus Local Equivalence Study in Asthma","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2014-10","conditions":"Asthma","enrollment":1128},{"nctId":"NCT02227394","phase":"PHASE2","title":"Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2014-08","conditions":"Asthma, Asthma Chronic, Asthma Bronchial","enrollment":20},{"nctId":"NCT01899144","phase":"PHASE2","title":"Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-07","conditions":"Asthma","enrollment":61},{"nctId":"NCT02031640","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":1113},{"nctId":"NCT02203474","phase":"PHASE2","title":"A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease","status":"WITHDRAWN","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-08","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":""},{"nctId":"NCT02040766","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":628},{"nctId":"NCT03474081","phase":"PHASE4","title":"A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":800},{"nctId":"NCT03590379","phase":"PHASE2","title":"Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2018-06-15","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":366},{"nctId":"NCT03137992","phase":"PHASE3","title":"Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness","status":"COMPLETED","sponsor":"Lupin, Inc.","startDate":"2017-11-21","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":377},{"nctId":"NCT04750603","phase":"PHASE4","title":"Effect of Fluticasone Furoate/Vilanterol on EIA in Adolescents","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"2018-12-01","conditions":"Asthma in Children","enrollment":92},{"nctId":"NCT03478696","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":732},{"nctId":"NCT03478683","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":729},{"nctId":"NCT00742248","phase":"PHASE2","title":"Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2004-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":54},{"nctId":"NCT03034915","phase":"PHASE4","title":"A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-06-16","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2696},{"nctId":"NCT02730351","phase":"PHASE4","title":"Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-05-25","conditions":"Asthma","enrollment":75},{"nctId":"NCT02291016","phase":"NA","title":"COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers","status":"COMPLETED","sponsor":"University of Tennessee Graduate School of Medicine","startDate":"2015-02","conditions":"COPD Exacerbation","enrollment":7},{"nctId":"NCT01494610","phase":"PHASE1, PHASE2","title":"Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT02777827","phase":"PHASE1","title":"A Single Dose PD & PK Study With Two Formulations of Abediterol in Patients With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-21","conditions":"Asthma","enrollment":30},{"nctId":"NCT02796677","phase":"PHASE3","title":"AMPLIFY - D6571C00001 Duaklir USA Phase III Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-07-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1595},{"nctId":"NCT02172443","phase":"PHASE3","title":"Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":50},{"nctId":"NCT02301975","phase":"PHASE3","title":"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-03-01","conditions":"Asthma","enrollment":1526},{"nctId":"NCT02345161","phase":"PHASE3","title":"A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-01-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1811},{"nctId":"NCT03110900","phase":"PHASE4","title":"Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2017-09-30","conditions":"Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use, Lorazepam Causing Adverse Effects in Therapeutic Use","enrollment":2},{"nctId":"NCT01706328","phase":"PHASE3","title":"A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":828},{"nctId":"NCT02487498","phase":"PHASE3","title":"Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-07-27","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":355},{"nctId":"NCT02207829","phase":"PHASE3","title":"A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1017},{"nctId":"NCT02487446","phase":"PHASE3","title":"Efficacy and Safety Study of QVA149 in COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-07-28","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":357},{"nctId":"NCT01817764","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":707},{"nctId":"NCT01879410","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-06-13","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":700},{"nctId":"NCT01181895","phase":"PHASE3","title":"Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-01","conditions":"Asthma","enrollment":348},{"nctId":"NCT02157935","phase":"PHASE3","title":"Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-06-27","conditions":"COPD Patients","enrollment":2026},{"nctId":"NCT00279019","phase":"PHASE1","title":"Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-12-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":31},{"nctId":"NCT01822899","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-04-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":717},{"nctId":"NCT01978145","phase":"PHASE3","title":"A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Fluticasone Propionate/Salmeterol (FSC) 250/50 Microgram (mcg) Through a Capsule-Based Inhaler and a Multi-Dose Inhaler Administered Twice Daily (BID) in Adults With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-11-14","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":665},{"nctId":"NCT00515502","phase":"PHASE2","title":"Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-21","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":24},{"nctId":"NCT01449799","phase":"PHASE1","title":"An Investigation of the Pharmacokinetics of GSK961081 and Fluticasone Propionate in Healthy Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-13","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":24},{"nctId":"NCT01978119","phase":"PHASE3","title":"A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol (FSC) 250/50 Microgram (mcg) Twice Daily (BID) in Adults and Adolescents With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-11-06","conditions":"Asthma","enrollment":124},{"nctId":"NCT01730404","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-10","conditions":"COPD","enrollment":55},{"nctId":"NCT00443482","phase":"PHASE2","title":"Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-02","conditions":"Asthma","enrollment":50},{"nctId":"NCT01641081","phase":"PHASE2","title":"Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-06","conditions":"Asthma","enrollment":174},{"nctId":"NCT01808339","phase":"PHASE2","title":"To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03","conditions":"Asthma","enrollment":28},{"nctId":"NCT01436110","phase":"PHASE3","title":"Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-09","conditions":"Asthma","enrollment":351},{"nctId":"NCT01462929","phase":"PHASE3","title":"Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":414},{"nctId":"NCT00403637","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-11","conditions":"Asthma","enrollment":45},{"nctId":"NCT02771717","phase":"PHASE4","title":"Low Exhaled NO and ICS in Suspected Asthma","status":"UNKNOWN","sponsor":"University of Nottingham","startDate":"2016-05","conditions":"Asthma","enrollment":165},{"nctId":"NCT01969721","phase":"PHASE3","title":"Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":229},{"nctId":"NCT02308098","phase":"PHASE3","title":"To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2014-12","conditions":"Asthma","enrollment":72},{"nctId":"NCT01709903","phase":"PHASE3","title":"A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":744},{"nctId":"NCT02242253","phase":"PHASE2","title":"Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":97},{"nctId":"NCT02242227","phase":"PHASE2","title":"Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":111},{"nctId":"NCT01040689","phase":"PHASE3","title":"Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":108},{"nctId":"NCT01040728","phase":"PHASE3","title":"A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":122},{"nctId":"NCT00793624","phase":"PHASE3","title":"Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":906},{"nctId":"NCT00796653","phase":"PHASE3","title":"Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":937},{"nctId":"NCT02172469","phase":"PHASE3","title":"Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":215},{"nctId":"NCT02172807","phase":"PHASE3","title":"Efficacy and Safety of Ba679BR Powder Inhalation in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":201},{"nctId":"NCT01126437","phase":"PHASE3","title":"Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":17183},{"nctId":"NCT00535366","phase":"PHASE2","title":"Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":103},{"nctId":"NCT02094274","phase":"PHASE1","title":"A Single-dose, Randomised, Crossover, Placebo-controlled Study Assessing Two Fixed-dose Combinations of Inhaled Long-acting Beta-agonist and Corticosteroid","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2013-11","conditions":"Asthma","enrollment":30},{"nctId":"NCT01613326","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":657},{"nctId":"NCT00350207","phase":"PHASE2","title":"Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-07","conditions":"Asthma","enrollment":388},{"nctId":"NCT01490125","phase":"PHASE3","title":"The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":247},{"nctId":"NCT00281567","phase":"PHASE3","title":"Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":76},{"nctId":"NCT00240435","phase":"PHASE3","title":"12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":491},{"nctId":"NCT00239473","phase":"PHASE3","title":"12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":429},{"nctId":"NCT01458886","phase":"PHASE2","title":"Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone","status":"WITHDRAWN","sponsor":"Boehringer Ingelheim","startDate":"2011-11","conditions":"Asthma","enrollment":""},{"nctId":"NCT01795664","phase":"PHASE3","title":"Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients","status":"COMPLETED","sponsor":"FLUIDDA nv","startDate":"2013-03","conditions":"Asthma","enrollment":16},{"nctId":"NCT01315249","phase":"PHASE3","title":"QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":523},{"nctId":"NCT00557440","phase":"PHASE2","title":"Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-11","conditions":"Asthma","enrollment":37},{"nctId":"NCT01294787","phase":"PHASE3","title":"Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-02","conditions":"COPD","enrollment":85},{"nctId":"NCT01348139","phase":"PHASE2","title":"Evaluation of the Pharmacokinetics and the Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 in Patients With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-05","conditions":"Asthma","enrollment":39},{"nctId":"NCT00396604","phase":"PHASE2, PHASE3","title":"Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-10","conditions":"Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive","enrollment":51},{"nctId":"NCT00669617","phase":"PHASE3","title":"Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":89},{"nctId":"NCT00529529","phase":"PHASE3","title":"Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-09","conditions":"Asthma","enrollment":805},{"nctId":"NCT00900731","phase":"PHASE3","title":"A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1598},{"nctId":"NCT01079130","phase":"PHASE3","title":"Efficacy and Safety of Different Doses of Indacaterol","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-02","conditions":"Asthma","enrollment":511},{"nctId":"NCT01089127","phase":"PHASE3","title":"Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":552},{"nctId":"NCT00567996","phase":"PHASE3","title":"Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1002},{"nctId":"NCT00393458","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1732},{"nctId":"NCT00821093","phase":"PHASE3","title":"Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1123},{"nctId":"NCT00463567","phase":"PHASE2, PHASE3","title":"26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-04","conditions":"Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive","enrollment":2059},{"nctId":"NCT00615459","phase":"PHASE3","title":"A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-02","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":169},{"nctId":"NCT00615030","phase":"PHASE3","title":"Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":96},{"nctId":"NCT00746330","phase":"PHASE2","title":"Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-08","conditions":"Asthma","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"marketed","status":"active","brandName":"Placebo - dummy inhaler","genericName":"Placebo - dummy inhaler","companyName":"University of Nottingham","companyId":"university-of-nottingham","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo inhaler delivers no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect. Used for Clinical trial control comparator (not a therapeutic indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}